Analyzing real-world treatment data for advanced skin cancer patients in Europe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry study aims to collect and analyze real-world data on patients with advanced non-melanoma skin cancer (NMSC), specifically basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), across various European regions. By utilizing the European NMSC-Registry, the study will describe patient characteristics, treatment patterns, and outcomes in routine clinical practice. The data collected will help address critical questions regarding the management of advanced NMSC and inform future treatment strategies. The study emphasizes the importance of accurate data recording and management to ensure the reliability of findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged ≥18 years at index date
2. Patients documented in the European NMSC-registry fulfilling EMR quality standard
3. Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting OR Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2) OR Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3)

Exclusion Criteria:

1\. Patients receiving treatment within a clinical trial.

Where it's running

• UZ (Universitair Ziekenhuis) Brüssel
  Brussels, Belgium Recruiting

Study contacts

• Study coordinator: Alexandra Hansen
• Email: alexandra.hansen@eumelareg.org
• Phone: +493037026901

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized immunotherapy platform for cancer treatment

  This study is testing a new way to identify melanoma and skin cancer patients who might not respond well to immunotherapy by analyzing their tumor samples.

  Recruiting at 3 sites Melanoma Institute Australia · Sydney, New South Wales and 2 other locations · NCT06536257

• MQ710 with or without pembrolizumab for advanced skin and other solid tumors

  This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.

  Recruiting at 5 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05859074

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

• AI-based risk and subtype prediction for basal cell carcinoma using dermoscopic images

  A retrospective study tests an artificial intelligence model to classify basal cell carcinoma as low- or high-risk and to predict histopathological subtypes from archived dermoscopic images.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Istanbul · NCT07677124

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.